Skip to main content
Clinical Trials/NCT01685853
NCT01685853
Completed
Phase 3

Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One. A Randomized, Observer-blind, Parallel Group, Comparative Study.

European Institute of Oncology1 site in 1 country164 target enrollmentApril 2011

Overview

Phase
Phase 3
Intervention
PEG 4 litres split
Conditions
Colonoscopy
Sponsor
European Institute of Oncology
Enrollment
164
Locations
1
Primary Endpoint
Efficacy
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The present study is intended to evaluate the effectiveness, tolerability, compliance, and feasibility of the low volume bowel preparation, bisacodyl tablets followed by 2L Polyethylene glycol (PEG) with citrate and simethicone (CS) given the same day of colonoscopy, vs the standard 4L split PEG solution.

Detailed Description

Eligible patients will be informed about the aims, procedures, benefits and possible risks of the study prior to sign the informed consent form from day -30 to day-3. They will provide medical history and undergo a physical examination. Patients will be evaluated by a Physician other than the blind Endoscopist. The same responsible person will instruct the patients about administration procedures in both oral and written form. The patients will be assigned to receive one of the dosing schedule bowel preparation according to a computer generated block-randomisation list. Patients will take the study treatment at home according to the given instructions. Patients will return to the clinic for colonoscopy. The colonoscopy will be performed by an Endoscopist who will be unaware of the bowel dose-regimen preparation taken by the patient. Completed colonoscopic exam will be performed with time recorded (intubation and withdrawal from ceacum). The unblind Investigator will ask the patients about safety, tolerability, overall acceptance and compliance.

Registry
clinicaltrials.gov
Start Date
April 2011
End Date
March 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
European Institute of Oncology
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Out-patients undergoing a complete colonoscopy
  • Patient written informed consent

Exclusion Criteria

  • Pregnant or lactating women or at a risk of becoming pregnant
  • Known or suspected gastrointestinal obstruction or perforation; toxic megacolon; major colonic resection Known or suspected hypersensitivity to the active principle and/or formulations' ingredients

Arms & Interventions

PEG 4 litres split

Polyethylene glycol with electrolytes (PEG)

Intervention: PEG 4 litres split

Bisacodyl plus PEG-CS

Bisacodyl plus PEG-CS: Bisacodyl plus Polyethylene glycol with citrate and simethicone (PEG-CS)

Intervention: Bisacodyl plus PEG-CS

Outcomes

Primary Outcomes

Efficacy

Time Frame: 20 min

Evaluation of the quality of bowel preparation according to the Ottawa Scale

Secondary Outcomes

  • Efficacy(20 min)
  • Safety(24 hours)
  • Tolerability(24 hours)
  • Acceptability(24 hours)
  • Compliance(24 hours)

Study Sites (1)

Loading locations...

Similar Trials